Ryan Beveridge

After completing an undergraduate degree in Molecular Biology at the University of Sussex I went on to undertake a PhD focussing on DNA Damage at the University of Sheffield. Following a short post-doc I transitioned into the gene therapy field with Oxford Biomedica where I performed upstream process development for a Lentiviral product. I was then given the opportunity to set up a new Virus Screening core facility at the University of Oxford (WIMM) allowing me to develop my understanding of a number of viral vector systems and a broader understanding of the model systems they are used for. I then worked with Oxgene on Lentiviral, AAV and Adenoviral upstream process development from 15mL bioreactors (ambr15) up to 10L reactors.

My role within the Clinical Biomanufacturing Facility is to manage the GMP production of novel IMPs for small scale phase I/II trials, ensuring all relevant standards of practise are met.